What Pinealon Is
Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), C15H26N6O8, 418.40 g/mol. Within the bioregulator family it is the central-nervous-system member, and it is one of the minority of the family with published work naming it directly.
It is also structurally distinctive: the arginine C-terminus makes it the only strongly basic tripeptide in the set, which is the property most often invoked in discussions of its distribution.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.
What the Published Studies Report
Cell viability and free-radical levels
The most-cited work reports that Pinealon increased cell viability by suppressing free radical levels and activating proliferative processes (Khavinson et al., Rejuvenation Res 2011, PMID 21978084). This is the study most often cited as the mechanistic basis for the neuroprotective association, and it is a cell-level result.
Prenatal hyperhomocysteinemia in rats
An independent group reported that Pinealon protected rat offspring from prenatal hyperhomocysteinemia (Arutjunyan et al., Int J Clin Exp Med 2012, PMID 22567179). This is a whole-animal developmental model and one of the few papers in the family from outside the originating group.
Behaviour under hypoxia and hypothermia
A study in 18-month-old rats examined the influence of Pinealon and Cortexin on behaviour and neurochemical processes under hypoxia and hypothermia (Mendzheritsky et al., Adv Gerontol 2015, PMID 28509493). Note that the design pairs Pinealon with a separate preparation, which limits what can be attributed to the tripeptide alone.
Reading the Evidence
Everything is animal or cell-level. There is no human study. The developmental model in rats is the strongest whole-organism evidence and it addresses one specific insult.
One study is a combination design. Where a compound is administered alongside another preparation, effects cannot be cleanly assigned to either.
No amount is established. No controlled human programme exists, so no figure is published for any context.
Structure and Handling
- Sequence. Glu-Asp-Arg (EDR), tripeptide.
- Formula. C15H26N6O8, 418.40 g/mol.
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
Related Compounds
Cortagen is the other CNS-associated member of the family and has its own literature, including work on injured nerve function. Epithalon shares the pineal origin. The full set is on our bioregulator overview.
Published Studies at a Glance
The table below consolidates the retrievable primary literature for Pinealon (EDR) as of mid-2026. The corpus is small: three publications meet the admissibility threshold of naming the tripeptide directly and reporting a measured outcome. No human trials appear in PubMed. Researchers should treat the body of evidence as hypothesis-generating rather than confirmatory.
| Study (first author, year) | Model | Reported dose / exposure | Primary outcome measured | Key finding | PMID |
|---|---|---|---|---|---|
| Khavinson et al., 2011 | In vitro — cell culture | Not publicly specified in abstract | Cell viability; free-radical levels; proliferative markers | Pinealon associated with increased viability, suppressed free-radical levels, and activation of proliferative processes | 21978084 [1] |
| Arutjunyan et al., 2012 | In vivo — Wistar rat offspring; prenatal hyperhomocysteinemia model | Peptide administered to dams; specific mg/kg not stated in abstract | Neurochemical and developmental outcomes in offspring | Pinealon reported to attenuate adverse developmental effects of elevated homocysteine in the prenatal period | 22567179 [2] |
| Mendzheritsky et al., 2015 | In vivo — 18-month-old Wistar rats; hypoxia + hypothermia challenge | Co-administered with Cortexin; individual Pinealon dose not isolated | Behavioural indices; neurochemical parameters | Combination associated with modified behavioural and neurochemical responses; Pinealon-specific contribution cannot be disaggregated from this design | 28509493 [3] |
Two methodological constraints recur across all three studies. First, the dose administered to animals is not consistently reported in retrievable abstracts, which makes cross-study comparison of exposure–response relationships impossible at this stage. Second, the 2015 combination design [3] means that any effect observed is attributable to the preparation pair, not to EDR alone. Researchers designing follow-on experiments should consider single-compound, dose-ranging protocols in rodent models as the logical next step before any higher-level inference is warranted.
Proposed Molecular Mechanism: What the Cell Data Suggest (and What Remains Untested)
Epistemic status of this section: proposed. The reasoning below is mechanistic inference grounded in the cell-culture findings reported by Khavinson et al. (2011) [1]. None of the steps described has been confirmed by a dedicated mechanistic study of EDR; none has been tested in humans.
The 2011 cell-viability paper reported two co-occurring observations: suppressed free-radical levels and activation of proliferative processes [1]. These findings are consistent with — but do not prove — a pathway in which EDR interacts with components of redox-sensitive transcriptional regulation. The arginine C-terminus of Glu-Asp-Arg is the structural feature most often invoked in discussions of the peptide's proposed CNS distribution, because basic residues at the C-terminus influence peptide stability toward carboxypeptidases and may modulate interaction with cell-surface proteoglycan components. However, no binding assay identifying a specific receptor or transporter for EDR has been published in the indexed literature.
The suppression of free-radical levels observed in vitro is consistent with multiple mechanistic possibilities: direct radical scavenging (plausible given the guanidinium group of arginine, which can participate in electron transfer), upregulation of endogenous antioxidant enzymes (e.g., superoxide dismutase, catalase), or attenuation of pro-oxidant signalling cascades. The data do not distinguish among these. Likewise, "activation of proliferative processes" is an outcome description, not a mechanism — it is consistent with effects on cyclin-dependent kinase activity, growth factor receptor signalling, or reduction of apoptotic flux, but the paper does not resolve which.
The prenatal hyperhomocysteinemia model [2] adds a second mechanistic context: homocysteine toxicity in neural tissue operates partly through oxidative stress and partly through NMDA-receptor overactivation. If Pinealon attenuates that insult, the site of action could be either arm. No experiment has tested these arms separately for EDR.
Summary of mechanistic unknowns: no receptor identified; no intracellular signalling cascade confirmed; no dose–response curve published for any proposed mechanism; no human pharmacokinetic data. The neuroprotective association observed in preclinical models is the observation; the mechanism explaining it remains an open question.
Structural Comparison with Related CNS Bioregulator Peptides
Pinealon belongs to a family of short synthetic peptides investigated by Khavinson and collaborators as tissue-specific bioregulators. Comparing EDR with two structurally adjacent members of that family — and with a separately developed CNS peptide, Semax — clarifies what is and is not distinctive about the Glu-Asp-Arg sequence. Chemical identity data below are drawn from PubChem structural records [4][5].
| Compound | Sequence | Formula | MW (g/mol) | Net charge at physiological pH | Proposed tissue focus | Human RCT evidence? |
|---|---|---|---|---|---|---|
| Pinealon (EDR) | Glu-Asp-Arg | C₁₅H₂₆N₆O₈ | 418.40 | Approximately neutral to weakly positive (Arg C-terminus) | CNS / pineal | None identified in PubMed |
| Epitalon (AEDG) | Ala-Glu-Asp-Gly | C₁₄H₂₂N₄O₉ | 390.34 | Negative (two acidic residues, no basic terminus) | Pineal / telomere biology | None identified in PubMed |
| Cortagen (Ala-Glu-Asp-Pro) | Ala-Glu-Asp-Pro | C₁₆H₂₄N₄O₉ | 420.37 | Negative | CNS (cortex) | None identified in PubMed |
| Semax (ACTH₄₋₇–Pro-Gly-Pro) | Met-Glu-His-Phe-Pro-Gly-Pro | C₃₇H₅₁N₉O₁₀S | 813.92 | Weakly negative | CNS (cognitive, BDNF-associated) | Limited; Russian clinical literature, variable registry status |
Three contrasts are worth noting for researchers choosing between these compounds. First, EDR's basic arginine terminus distinguishes it from Epitalon and Cortagen, both of which carry net negative charge — a difference that may influence interaction with negatively charged membrane surfaces and peptidase susceptibility, though no comparative pharmacokinetic study has been published. Second, Semax is a heptapeptide derived from the ACTH₄₋₇ sequence with an added Pro-Gly-Pro stabilising extension; it has a documented proposed mechanism (BDNF pathway modulation, MC receptor engagement) that is more developed in the literature than EDR's mechanism, though still predominantly preclinical. Third, Pinealon and Epitalon share two of three residues (Glu and Asp) and both are associated with pineal-region biology in the bioregulator framework, yet their sequences, charges, and molecular weights differ sufficiently that evidence for one cannot be transferred to the other. This point applies with equal force within the bioregulator family: a result reported for Epitalon is not evidence about EDR, and vice versa.
Note on Cortagen: PubMed returns very limited indexed English-language literature on Cortagen as a distinct compound; the comparison row above is based on structural inference from the bioregulator framework and should not be read as implying equivalent research depth.
